The Weekly Roundup: July 1-5

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Dermatology Conferences and Meetings Calendar 2024: July

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

The Role of Online Patient-Oriented Platforms in Dermatology

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

Pyzchiva will be commercialized by Sandoz in the United States.

The Role of Dermatology in Habit Reversal Therapy

A recent review found success from a 3-component, simplified habit reversal therapy implemented by dermatologists for BFRBs.

Addressing Acne Scarring Concerns Among Patients

With the latest advancements in dermatology, there is a great range of treatments available to address the various types of acne scarring.

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

Case Report: Efficacy of Dupilumab for Acquired Reactive Perforating Collagenosis Associated with Atopic Dermatitis

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

Embracing Diversity and Cultural Competence

Adopting diversity management is not just a choice but a pressing need in the evolving health care landscape.

Eczema Expo Research, Panel Shed Light on Relationship Between Eczema and Mental Health

Recent research and conversations shared at the National Eczema Association expo tackled the link between patient well-being and eczema.

ICYMI: FDA Approves RhodoLED XL Lamp Red Light Source for Use in Actinic Keratosis Treatment

Biofrontera's red light source is approved for use in combination with aminolevulinic acid hydrochloride (Ameluz) topical gel, 10%.

Active Complex Anti-Aging Eye Cream Shows Promise

A recent study found that subjects reported an improvement in elasticity and firmness, with decreased fine lines and wrinkles after 8 and 12 weeks of use.

Preparing for 4th of July Skin Emergencies

Explore evidence-based clinical recommendations for fireworks burns, chlorine irritation, and more.

Exploring the Intersection of Permanent Makeup and Dermatology

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.

Only 25.5% of Hungarian Dermatologists Report Comfortability in Treating Psychodermatological Patients

As many as 76.5% of participants could not name any psychodermatology resources, while only 58.8% were definitively interested in training on the topic.

Factors Influencing Margin Clearance and Number of Stages of Mohs Surgery in BCC Management

A recent study offers a comprehensive analysis of practice patterns and patient characteristics in different clinical settings.

Celebrating 45 Years of Education

The first issue of Dermatology Times was published in 1979 to offer clinical insights into a growing health care specialty.

Q&A: Mona Shahriari, MD, FAAD, Talks Multidisciplinary Care

Shahriari spoke about the importance of comprehensive care, collaborating with other specialists, and addressing psychosocial impact.

Caring for Patients: Lessons From My Podiatrist Parents and Other Amazing Mentors

Dermatology Times' Summer Editor in Chief, Shanna Miranti, MPAS, PA-C, shares how she has learned to be happy, stay humble, and be brilliant in her more than 22 years in dermatology.

Addressing Sunscreen Safety: A Review of EWG’s 2024 Guide to Sunscreens

Adewole Adamson, MD, MPP, discusses the Environmental Working Group's 2024 Guide to Sunscreens and what clinicians should discuss with patients who express concerns with the headlines stemming from the report.

Deucravacitinib Shows Promise as Oral Psoriasis Treatment

Phase 3 trials found the treatment demonstrated efficacy as early as week 1 of treatment and sustained this response through week 52.